Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real‐World Analysis of the <scp>IMMUreal</scp> Cohort
Sequential therapy following atezolizumab and bevacizumab is feasible only for selected patients. However, preserving liver function seems crucial to optimising multi-line therapy and improving outcomes in advanced hepatocellular carcinoma.
Authors
- Ignazio Piseddu (ORCID: https://orcid.org/0000-0001-8331-9778)
- Florian Paul Reiter (ORCID: https://orcid.org/0000-0003-3807-1456)
- Julia V. Mayerle (ORCID: https://orcid.org/0000-0002-3666-6459)
- Ursula Ehmer (ORCID: https://orcid.org/0000-0002-0441-1953)
- Najib Ben Khaled (ORCID: https://orcid.org/0000-0002-9681-2542)
- Michael T. Dill (ORCID: https://orcid.org/0000-0002-1926-4204)
- Monika Rau
- Hans Benno Leicht
- Andreas Geier (ORCID: https://orcid.org/0000-0002-9626-5083)
- Enrico Narciso De Toni (ORCID: https://orcid.org/0000-0002-8101-8207)
- Matthias Pinter (ORCID: https://orcid.org/0000-0002-7260-532X)
- Alexander Weich (ORCID: https://orcid.org/0000-0002-4127-1347)
- Arne Kandulski (ORCID: https://orcid.org/0009-0005-9065-8395)
- Bernard Hobeika
- Valentina Zarka
- Peter Schirmacher
- Jens U. Marquardt (ORCID: https://orcid.org/0000-0002-8314-2682)
- Liangtao Ye (ORCID: https://orcid.org/0000-0003-4364-9494)
- Julia Schneider
Institutions
- Sun Yat-sen University (CN)
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- LMU Klinikum (DE)
- University Hospital Regensburg (DE)
- The Seventh Affiliated Hospital of Sun Yat-sen University (CN)
- National Center for Tumor Diseases (DE)
- Universitätsklinikum Würzburg (DE)
- Technical University of Munich (DE)
- Medical University of Vienna (AT)
- Ludwig-Maximilians-Universität München (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Alimentary Pharmacology & Therapeutics
- Published
- 2025-04-04
- DOI
- https://doi.org/10.1111/apt.70090
- Citations
- 4
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 5.29